Evidence map›Paper›PMID 40116568›Full record

ArticleLung cancer management2025

Pooled analysis of oral vinorelbine as single agents in patients with advanced NSCLC.

Christos Chouaid, Francesco Grossi, Christine Ta Thanh Minh, Romain Raymond, Joaquim Bosch-Barrera

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Lung cancer management, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

Christos ChouaidPneumology, CH Intercommunal de Créteil, Créteil, France.
Francesco GrossiDepartment of Medicine and Technological Innovation, Università degli Studi dell'Insubria, Varese - Medical Oncology Division, ASST Sette Laghi, Varese, Italy.
Christine Ta Thanh MinhMedical & Patient/Consumer Division, Pierre Fabre, Boulogne-Billancourt, France.
Romain RaymondMedical & Patient/Consumer Division, Pierre Fabre, Boulogne-Billancourt, France.
Joaquim Bosch-BarreraDepartment of Medical Oncology, Catalan Institute of Oncology, Doctor Josep Trueta University Hospital; Precision Oncology Group (OncoGIR-Pro), Institut d'Investigació Biomèdica de Girona (IDIBGI); Department of Medical Sciences, Medical School, University of Girona, Girona, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesThis was a pooled analysis of data from weekly vinorelbine (VNR) treatment arms of four individual open-label, phase II studies to assess and refine the efficacy and tolerance of weekly oral VNR in a larger cohort of patients with advanced NSCLC. MATERIALS AND

methodsAll patients included in this pooled analysis received oral VNR at the dose of 60 mg/m

resultsA total of 247 patients were included. The ORR and DCR were 8.9% and 57.5% respectively, median PFS and OS were 3.3 and 8.5 months, respectively. Less than half (40.7%) of patients reported ≥1 serious AE (regardless of causality), with 12.3% reporting ≥1 treatment-related serious AE (grade ≥3: 11.1%). The most reported grade ≥3 AEs were neutropenia (17.6%), fatigue (5.8%), and decreased appetite (4.9%).

conclusionThis pooled analysis showed that weekly oral VRN is a valid option, with an acceptable safety profile, in this population of patients with advanced NSCLC, confirming results from previous individual studies.

Indexed as

Advanced NSCLCfirst-line chemotherapymonotherapyoral vinorelbinepooled efficacypooled safety

Identifiers

PMID40116568
PMCPMC11938966

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.